Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate

NCT01688830 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

157

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Dabigatran
DRUG: BI 655075
DRUG: Placebo

Sponsor

Boehringer Ingelheim